Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
- Registration Number
- NCT05005312
- Lead Sponsor
- Pfizer
- Brief Summary
The study is to estimate the effect of hepatic impairment on the plasma PK of PF-07321332/ritonavir. Findings from this study will be used to develop dosing recommendations so that the dose and/or dosing interval may be adjusted appropriately in the presence of hepatic impairment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 17
- Male and female participants who are classically healthy having no clinically relevant abnormalities. No known or suspected hepatic impairment
- Stable hepatic impairment that meets the criteria for Class B of the Child-Pugh Classification
- Any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection).
- Participants who have been vaccinated with COVID-19 vaccines within the past week of dosing
- A positive urine drug test, for illicit drugs, at Screening
- History of sensitivity reactions to ritonavir or any of the formulation components of PF-07321332 or ritonavir.
- eGFR <60 mL/min/1.73m2 based on the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥ upper limit of normal (ULN) (for healthy participants); AST or ALT > 5x ULN (for hepatic impairment participants)
- Albumin > ULN (for healthy participants);
- Prothrombin time > ULN (for healthy participants);
- Total bilirubin level ≥1.5 × ULN [NOTE: Participants with a history of Gilbert syndrome (and hence elevated total bilirubin) are eligible provided direct bilirubin level is ≤ ULN).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 2 PF-07321332 Hepatic Impairment Cohort 1 PF-07321332 Healthy Volunteer Cohort 1 Ritonavir Healthy Volunteer Cohort 2 Ritonavir Hepatic Impairment
- Primary Outcome Measures
Name Time Method Maximum Observed Plasma Concentration (Cmax) of Plasma PF-07321332 Day 1 at 0 (pre-dose for PF-07321332), 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours, Day 2 at 24 and 36 hours, and Day 3 at 48 hours Cmax was the maximum observed plasma concentration and was directly observed from data. Concentration values below the lower limit of quantification (LLQ) were set to zero. Geometric mean analysis was on the log scale. Zero values were not included in geometric mean and geometric coefficient of variation calculation. The geometric coefficient of variation was expressed in percentage.
Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-07321332 Day 1 at 0 (pre-dose for PF-07321332), 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours, Day 2 at 24 and 36 hours, and Day 3 at 48 hours AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration. The geometric coefficient of variation was expressed in percentage.
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-07321332 Day 1 at 0 (pre-dose for PF-07321332), 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours, Day 2 at 24 and 36 hours, and Day 3 at 48 hours AUCinf was defined as area under the plasma concentration-time curve from time zero to infinity. The geometric coefficient of variation was expressed in percentage.
- Secondary Outcome Measures
Name Time Method Number of Participants With an Treatment Emergent Adverse Event (TEAE) Up to 2 months An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse event (TEAE) means event between first dose of study treatment and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of death; inpatient hospitalization; life-threatening experience; disability; congenital anomaly or deemed significant for any other reason.
Number of Participants With Abnormal Electrocardiograms (ECGs) Up to 2 months ECG categorical summarization criteria: 1. PR interval (the interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization): a) greater than or equal to (\>=) 300 millisecond (msec), b) \>=25% increase when baseline is \> 200 msec or \>=50% increase when baseline is less than or equal to (\<=) 200 msec.
2. QRS duration (time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization): a) \>=140 msec, b) \>=50% increase from baseline.
3. QTcF interval (QT corrected using the Fridericia formula): a) \>450 msec and \<=480 msec, b) \>480 msec and \<=500 msec, c) \>500 msec, d) \>30 msec and \<=60 msec increase from baseline, e) \>60 msec increase from baseline.Number of Participants With Abnormal Vital Signs Up to 2 months Criteria for vital signs abnormalities: increase or decrease from baseline in systolic blood pressure (SBP) \>=30 mm Hg and increase or decrease from baseline in diastolic blood pressure (DBP) \>=20 mm Hg; the value of SBP \<90 mm Hg; the value of DBP \<50 mm Hg; the value of pulse rate \<40 bpm or \>120 bpm.
Number of Participants With Abnormal Laboratory Assessments (Without Regard to Baseline Abnormality) Up to 2 months Following laboratory parameters were assessed against pre-defined abnormality criteria: hematology; clinical chemistry; urinalysis.
Trial Locations
- Locations (2)
Prism Research LLC dba Nucleus Network
🇺🇸Saint Paul, Minnesota, United States
Orange County Research Center
🇺🇸Tustin, California, United States